Korean J Dermatol.
2008 Oct;46(10):1357-1361.
Multicenter Survey of the Efficacy and Compliance with UsingTopical Pimecrolimus by Patients with Atopic Dermatitis
- Affiliations
-
- 1Department of Dermatology, College of Medicine, Chung-Ang University, Korea.
- 2Department of Dermatology, College of Medicine, Seoul National University, Korea.
- 3Department of Dermatology, College of Medicine, Kyungpook National University, Korea.
- 4Department of Dermatology, College of Medicine, Hanyang University, Korea.
- 5Department of Dermatology, College of Medicine, Hallym University, Korea.
- 6Department of Dermatology, College of Medicine, Chonnam University, Korea.
- 7Department of Dermatology, College of Medicine, Dongguk University, Korea.
- 8Department of Dermatology, College of Medicine, University of Ulsan, Korea.
- 9Department of Dermatology, College of Medicine, Yonsei University, Korea. kwanglee@yuhs.ac
Abstract
- BACKGROUND
Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disease that's influenced by many genetic and environmental factors. Various treatment modalities are being applied for AD, including phototherapy, topical applicants and systemic agents. However, there has been no mass survey in Korea concerning the compliance of patients' to use their prescribed medication, which might influence the clinical efficacy of the physicians' treatment.
OBJECTIVE
The purpose of the present study is to evaluate the efficacy, safety and patient compliance with using topical pimecrolimus to treat AD.
METHODS
We reviewed the medical recordings, laboratory profiles, clinical severity scoring and photographs of AD patients at 9 general hospitals in Seoul and the local area of Korea. Interviews with the patients and a telephone survey were also done. Those patients who weren't perscribed topical applicants or those who did not use topical pimecrolimus or steroid within 6 months were excluded from this study.
RESULTS
Topical pimecrolimus cream effectively controlled AD with a reduction of the EASI score from baseline 13.75 to 11.39 at 2 weeks and 4.46 at 10 weeks of topical pimecrolimus application. When topical pimecrolimus cream was applied for more than 12 months it significantly suppressed the recurrence and reactivation of AD (p<0.05). Although 22.6% of the patients complained of adverse effects, these were all transient and they did not evoke significant medical problems. Using topical pimecrolimus cream did not show significant adverse effects or complications.
CONCLUSION
Topical pimecrolimus might well be an effective treatment modality for treating AD when patients show good compliance for applying the cream.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Three Cases of Facial Atopic Dermatitis Treated with Topical Pimecrolimus (Elidel)
- Knowledge, Compliance and Quality of Life of Mothers of Children with Atopic Dermatitis
- Allergen-specific Immunotherapy in Patients with Atopic Dermatitis
- Measurement of Atopic Dermatitis Disability
- Serum IgE Level in Patients of Atopic Dermatitis and Atopic Dermatitis with Molluscum Contagiosum
